ClinicalTrials.gg
Drug

Relacorilant clinical trials

Also written CORT125134.

studies test it
26
open now
4
in phase 3
4
first study started
2014

How each study uses relacorilant is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the relacorilant studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
25 Mar 2026 · LIFYORLI (COPACKAGED) · NDA 220641 (FDA, Drugs@FDA)
European Union
Not in EMA's list of EU-wide authorizations

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Relacorilant
15

Brand

Lifyorli
1

Development codes

CORT125134
18

Studies by the year they started

26 studies that test it; most in 2018 (7)

Studies that test relacorilant, by start year
YearStudies
20141
20164
20171
20187
20191
20205
20211
20222
20251
20263

By phase

A phase 1/2 study counts in both.

Phase 1
16
Phase 2
8
Phase 3
4

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 22 · Other 4

Corcept Therapeutics (22) · University of Chicago (2) · The University of Texas Health Science Center at San Antonio (1) · ARCAGY/ GINECO GROUP (1)

Often tested with

Tested in the same studies.

Albumin-Bound Paclitaxel (4) · Paclitaxel (4) · Itraconazole (1) · Prednisone (1) · Glucose (1) · Midazolam (1) · Metoprolol (1) · Pioglitazone (1)

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Reaching primary completion within a year · 3

Studies that test relacorilant.

Studies

Open first, then newest update. How each study uses relacorilant is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 26

See all 26 studies that test relacorilant →

Given beside what is tested · 1 — relacorilant is usual care or a partner of the new treatment

What changed recently

From the registry's own updates since Oct 18, 2026.

Codes

What other systems call relacorilant · ClinicalTrials.gg INT001143

  • MeSH (NLM) C000633444relacorilantOne source NLM
  • UNII (FDA) 2158753C7ERELACORILANTConfirmed FDA, NLM, Wikidata
  • Wikidata Q48845466relacorilantConfirmed FDA, NLM, Wikidata
  • NCI Thesaurus C127838RelacorilantOne source FDA
  • DrugBank DB14976One source Wikidata

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.